Latest Articles

Publication Date
Mood lability and depression limit oral contraceptive therapy in endometriosis.

To determine the impact of oral contraceptive (OC) induced mood lability/depression on treatment maintenance in women with endometriosis.

Published: Dec. 11, 2024, midnight
Peri-implantation treatment with TNF-α inhibitor for endometriosis and/or adenomyosis women undergoing frozen-thawed embryo transfer: A retrospective cohort study.

Endometriosis and adenomyosis have common pathogenesis and close relationship, with multi-factors involved in related infertility and IVF failure. They lead to anatomical changes, ovarian reserve reduction, endocrine abnormalities, altered endometrial …

Published: Dec. 11, 2024, midnight
Management of endometriosis: a call to multidisciplinary approach.

Endometriosis is defined as the presence of endometrial-like glands and stroma outside of the uterus. There are three types of endometriotic lesions: superficial or peritoneal endometriosis, ovarian endometrioma, and deep …

Published: Dec. 10, 2024, midnight
Top Gynecologic Cancer Research of 2024 - Cancer Therapy Advisor

Top Gynecologic Cancer Research of 2024 Cancer Therapy Advisor

Published: Dec. 9, 2024, 3 p.m.
Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer - OncLive

Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer OncLive

Published: Dec. 5, 2024, 7:04 p.m.
The Role of GnRH Agonist Therapy and Hysterosalpingography (HSG) in Diagnosing and Treating Tubal Factor Infertility.

The paper describes the treatment of a 27-year-old woman with a history of infertility, heavy menstrual periods, and severe endometriosis with bilateral hydrosalpinx. The patient received hormonal treatment with triptorelin …

Published: Dec. 5, 2024, midnight
NMPA greenlights new endometrial cancer therapy - Investing.com India

NMPA greenlights new endometrial cancer therapy Investing.com India

Published: Dec. 4, 2024, 1:01 a.m.
Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | IVBIY Stock News - StockTitan

Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | IVBIY Stock News StockTitan

Published: Dec. 4, 2024, 12:01 a.m.
Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | HCM Stock News - StockTitan

Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | HCM Stock News StockTitan

Published: Dec. 4, 2024, midnight
Elagolix with add-back therapy found effective and tolerable for endometriosis pain - Contemporary Obgyn

Elagolix with add-back therapy found effective and tolerable for endometriosis pain Contemporary Obgyn

Published: Dec. 3, 2024, 6:36 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!